Relationships between phosphatidic acid and cyclic nucleotide phosphodiesterases in activated human blood mononuclear cells

J Leukoc Biol. 1999 Mar;65(3):381-90. doi: 10.1002/jlb.65.3.381.

Abstract

We have previously shown that mitogenic activation of human PBMC rapidly increases both the intracellular phosphatidic acid (PA) level and cyclic nucleotide phosphodiesterase (PDE) activity, with time-course responses, suggesting a causative relationship between the two events. PA also directly stimulated cAMP-PDE activity in acellular systems. Thus the mitogenic properties of PA night be due to its ability to lower the level of cAMP, a negative effector of lymphocyte activation, through PDE activation. In this study, human PBMC were stimulated either with the mitogenic lectin ConA, the anti-CD3 mAb OKT3, or the phorbol ester TPA. All three agonists increased the radiolabeled PA level and the PA mass in treated cells and simultaneously increased cytosolic and particulate cAMP- and cGMP-PDE activities, with significant positive correlations between PA accumulation and PDE activities. Furthermore, the ConA-induced PDE activation was dose-dependently reduced by treatment of PBMC with the diacylglycerol-kinase inhibitor R59022. This compound also dose-dependently lowered the PA level and inhibited the proliferative response to ConA. In addition, TPA-induced PDE activation was totally abolished by ethanol, which strongly reduced PA accumulation in response to the phorbol ester. These data suggest that PA increase may be linked to mitogen-induced PDE activation. Experiments performed in the presence of rolipram indicated that ConA and TPA stimulated both the rolipram-sensitive PDE4 and the rolipram-insensitive PDE activities, OKT3 being more active on PDE4. All three agonists stimulated the cGMP-specific PDE5. These results suggest that PA is an important component of the mechanisms that maintain a low level of cyclic nucleotides, which is a prerequisite for an optimal lymphoproliferative response.

MeSH terms

  • 3',5'-Cyclic-AMP Phosphodiesterases / metabolism*
  • Cell Division / drug effects
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Leukocytes, Mononuclear / cytology
  • Leukocytes, Mononuclear / metabolism*
  • Mitogens / pharmacology
  • Muromonab-CD3 / pharmacology
  • Phosphatidic Acids / metabolism*
  • Pyrimidinones / pharmacology
  • Thiazoles / pharmacology

Substances

  • Enzyme Inhibitors
  • Immunosuppressive Agents
  • Mitogens
  • Muromonab-CD3
  • Phosphatidic Acids
  • Pyrimidinones
  • Thiazoles
  • R 59022
  • 3',5'-Cyclic-AMP Phosphodiesterases